About Xinvento
Xinvento is a company based in Amsterdam (Netherlands) founded in 2021 by Sarah Hafith and Piet Wigerinck was acquired by Rhythm Pharmaceuticals in February 2023. Xinvento offers products and services including CHI Treatment.
- Headquarter Amsterdam, Netherlands
- Founders Sarah Hafith, Piet Wigerinck
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Xinvento Bv
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Rhythm Pharmaceuticals
& 8 more
-
Employee Count
Not available
-
Acquired by
Rhythm Pharmaceuticals
(Feb 27, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xinvento
Xinvento offers a comprehensive portfolio of products and services, including CHI Treatment.
Developing alternative treatments to manage congenital hyperinsulinism symptoms effectively.
People of Xinvento
Unlock access to complete
Unlock access to complete
Funding Insights of Xinvento
Investors in Xinvento
Xinvento has secured backing from 9 investors, including angel investors. Prominent investors backing the company include Rhythm Pharmaceuticals, Ed Kaye and John Maraganore.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EK
Ed Kaye |
-
|
Locked | Locked | Locked |
|
JM
John Maraganore |
-
|
Locked | Locked | Locked |
|
DM
David Meeker |
Angel investor focusing on Indian startups, limited public data available.
|
Locked | Locked | Locked |
Investor details for Xinvento
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xinvento
Investment portfolio details for Xinvento
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xinvento
Detailed financials for Xinvento
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xinvento Comparisons
Peer comparison for Xinvento
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xinvento
Detailed competitors of Xinvento
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xinvento
Complete news archive for Xinvento
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xinvento
Xinvento was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Xinvento is headquartered in Amsterdam, Netherlands.
Xinvento was founded in 2021 and is based in Amsterdam, Netherlands. Focus is placed on the research and development of treatments for congenital hyperinsulinism, a rare disease marked by persistent hypoglycemia. Operations center on advancing therapies within the biotechnology sector to address this condition, with activities conducted primarily in Europe. Key personnel include co-founders Sarah Hafith and Piet Wigerinck.
Xinvento offers CHI Treatment.
Xinvento has 9 investors. Key investors include Rhythm Pharmaceuticals, Ed Kaye, John Maraganore, David Meeker, and James Shannon.